melatonin has been researched along with Behavior Disorders in 80 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the usefulness of melatonin for sleep disorders and emotional/behavior disturbances of patients with developmental disorders." | 9.09 | [Usefulness of melatonin for developmental sleep and emotional/behavior disorders--studies of melatonin trial on 50 patients with developmental disorders]. ( Ishizaki, A; Sugama, M; Takeuchi, N, 1999) |
| "There is emerging evidence of the beneficial role of the melatonin system in a wide range of psychiatric and neurologic disorders, including anxiety, depression, and epilepsy." | 8.91 | The role of the melatoninergic system in epilepsy and comorbid psychiatric disorders. ( Fusco, AD; Moyanova, S; Ngomba, RT; Tchekalarova, J, 2015) |
| "Melatonin is an ancient molecule that is evident in high concentrations in various tissues throughout the body." | 6.72 | Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders. ( Brown, GM; Gonçalves, VF; Kennedy, JL; Melhuish Beaupre, LM, 2021) |
| "Treatment with melatonin is useful in a diverse range of medical conditions, including bipolar disorder, Alzheimer's disease, depression and fibromyalgia." | 6.50 | Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. ( Anderson, G; Maes, M, 2014) |
| "Our results show that melatonin is effective in attenuating SGAs' adverse metabolic effects, particularly in bipolar disorder." | 5.19 | Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. ( Alvarez-Icaza González, D; Becerra-Palars, C; Berlanga, C; Buijs, RM; Fresán-Orellana, A; Heinze, G; Moreno, J; Ontiveros Uribe, MP; Romo-Nava, F; Saracco Alvarez, R, 2014) |
| "We studied the usefulness of melatonin for sleep disorders and emotional/behavior disturbances of patients with developmental disorders." | 5.09 | [Usefulness of melatonin for developmental sleep and emotional/behavior disorders--studies of melatonin trial on 50 patients with developmental disorders]. ( Ishizaki, A; Sugama, M; Takeuchi, N, 1999) |
| "There is emerging evidence of the beneficial role of the melatonin system in a wide range of psychiatric and neurologic disorders, including anxiety, depression, and epilepsy." | 4.91 | The role of the melatoninergic system in epilepsy and comorbid psychiatric disorders. ( Fusco, AD; Moyanova, S; Ngomba, RT; Tchekalarova, J, 2015) |
| "The aim of this review was to summarize the potential use of melatonin in the treatment of mental disorders, specifically bipolar disorders, depression, and schizophrenia." | 4.85 | Melatonin as a potential therapeutic agent in psychiatric illness. ( Maldonado, MD; Pérez-San-Gregorio, MA; Reiter, RJ, 2009) |
| "The prevalence of type 2 diabetes is increased in individuals with mental disorders." | 2.72 | Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries. ( Ajjan, RA; Al Azdi, Z; Aslam, F; Churchill, R; Mishu, MP; Philip, S; Siddiqi, N; Stubbs, B; Tirbhowan, N; Uphoff, E; Wright, J, 2021) |
| "Melatonin is an ancient molecule that is evident in high concentrations in various tissues throughout the body." | 2.72 | Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders. ( Brown, GM; Gonçalves, VF; Kennedy, JL; Melhuish Beaupre, LM, 2021) |
| "Treatment with ritanserin appeared to be ineffective." | 2.67 | Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. ( Den Boer, JA; Westenberg, HG, 1990) |
| " However, there is still uncertainty concerning dosing regimens and a lack of other data." | 2.61 | Pediatric sleep disturbances and treatment with melatonin. ( Argentiero, A; D'Alonzo, R; Di Genova, L; Esposito, S; Fattorusso, A; Laino, D; Mencarelli, A; Mencaroni, E, 2019) |
| "Melatonin is a molecule with numerous properties applicable to the treatment of neurological diseases." | 2.55 | Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders. ( Martinez-Cue, C; Mediavilla, MD; Reiter, RJ; Rueda, N; Sanchez-Barcelo, EJ, 2017) |
| "Melatoninergic agonists have been shown to reliably entrain circadian rhythms, if chronobiological phase response rules are followed." | 2.53 | Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches. ( Hardeland, R, 2016) |
| "Sleep disorders and neurodegenerative diseases are commonly encountered in primary care." | 2.53 | Importance of Rapid Eye Movement Sleep Behavior Disorder to the Primary Care Physician. ( Howell, MJ; McCarter, SJ, 2016) |
| "Pediatric insomnia is an extrinsic sleep disorder subdivided into two categories: behavioral insomnia and insomnia related to medical, neurological, and psychiatric diseases." | 2.50 | Pediatric insomnia: clinical, diagnosis, and treatment. ( Miano, S; Peraita-Adrados, R, 2014) |
| "Treatment with melatonin is useful in a diverse range of medical conditions, including bipolar disorder, Alzheimer's disease, depression and fibromyalgia." | 2.50 | Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. ( Anderson, G; Maes, M, 2014) |
| "Melatonin is a highly pleiotropic regulator molecule, which influences numerous functions in almost every organ and, thus, up- or down-regulates many genes, frequently in a circadian manner." | 2.50 | Melatonin, noncoding RNAs, messenger RNA stability and epigenetics--evidence, hints, gaps and perspectives. ( Hardeland, R, 2014) |
| " The recognition of the periodicity of biological processes makes the optimal dosing of certain drugs feasible." | 2.48 | [Physiological and pathophysiological role of the circadian clock system]. ( Halmos, T; Suba, I, 2012) |
| "Melatonin is an endocrine output signal of the clock and provides circadian information as an endogenous synchronizer which stabilizes and reinforces circadian rhythms." | 2.44 | Melatonin, consciousness, and traumatic stress. ( Bob, P; Fedor-Freybergh, P, 2008) |
| "Circadian Rhythm Sleep Disorders (CRSD) are a group of sleep disorders characterized by a de-synchronization between a person's biological clock and the environmental 24-hour schedule." | 2.41 | Circadian Rhythm Sleep Disorders (CRSD) in psychiatry--a review. ( Dagan, Y, 2002) |
| "Treatment with melatonin was associated with suicide and suicide attempt." | 1.72 | Associations between treatment with melatonin and suicidal behavior: a nationwide cohort study. ( Erlangsen, A; Hawton, K; Høier, NK; Jennum, P; Madsen, T; Nordentoft, M; Spira, AP, 2022) |
| "Melatonin is a hormone secreted by the pineal gland at night." | 1.51 | The use of melatonin in adult psychiatric disorders: Expert recommendations by the French institute of medical research on sleep (SFRMS). ( Geoffroy, PA; Lopez, R; Micoulaud Franchi, JA; Schroder, CM, 2019) |
| "Melatonin is a drug widely used, particularly for electroencephalogram in children." | 1.43 | Efficiency of Melatonin as Compared to Pentobarbital for Audiometry Brainstem Response in Children With Associated Disorders. ( Garabedian, EN; Guerlain, J; Loundon, N; Parodi, M; Paul, A; Rouillon, I, 2016) |
| "Treatment with melatonin led to significant decrease in oxidative injury." | 1.35 | Levels of oxidative stress parameters and the protective effects of melatonin in psychosis model rat testis. ( Akbas, A; Ozyurt, B; Ozyurt, H; Parlaktas, BS; Tunc, AT, 2008) |
| "Melatonin synthesis was just becoming apparent at 2100h." | 1.28 | Human melatonin response to light at different times of the night. ( Armstrong, SM; Burrows, GD; McIntyre, IM; Norman, TR, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (18.75) | 18.7374 |
| 1990's | 11 (13.75) | 18.2507 |
| 2000's | 19 (23.75) | 29.6817 |
| 2010's | 29 (36.25) | 24.3611 |
| 2020's | 6 (7.50) | 2.80 |
| Authors | Studies |
|---|---|
| Starr, KE | 1 |
| Burns, K | 1 |
| Demler, TL | 1 |
| Lim, S | 1 |
| Park, S | 1 |
| Koyanagi, A | 1 |
| Yang, JW | 1 |
| Jacob, L | 1 |
| Yon, DK | 1 |
| Lee, SW | 1 |
| Kim, MS | 1 |
| Il Shin, J | 1 |
| Smith, L | 1 |
| Høier, NK | 1 |
| Madsen, T | 1 |
| Spira, AP | 1 |
| Hawton, K | 1 |
| Jennum, P | 1 |
| Nordentoft, M | 1 |
| Erlangsen, A | 1 |
| Mishu, MP | 1 |
| Uphoff, E | 1 |
| Aslam, F | 1 |
| Philip, S | 1 |
| Wright, J | 1 |
| Tirbhowan, N | 1 |
| Ajjan, RA | 1 |
| Al Azdi, Z | 1 |
| Stubbs, B | 1 |
| Churchill, R | 1 |
| Siddiqi, N | 1 |
| Melhuish Beaupre, LM | 1 |
| Brown, GM | 1 |
| Gonçalves, VF | 1 |
| Kennedy, JL | 1 |
| Romo-Nava, F | 2 |
| Buijs, RM | 2 |
| McElroy, SL | 1 |
| Tordjman, S | 1 |
| Chokron, S | 1 |
| Delorme, R | 1 |
| Charrier, A | 1 |
| Bellissant, E | 1 |
| Jaafari, N | 1 |
| Fougerou, C | 1 |
| Sanchez-Barcelo, EJ | 1 |
| Rueda, N | 1 |
| Mediavilla, MD | 1 |
| Martinez-Cue, C | 1 |
| Reiter, RJ | 3 |
| Carpentieri, AR | 1 |
| Peralta Lopez, ME | 1 |
| Aguilar, J | 1 |
| Solá, VM | 1 |
| Kamath, A | 1 |
| Rather, ZA | 1 |
| Esposito, S | 1 |
| Laino, D | 1 |
| D'Alonzo, R | 1 |
| Mencarelli, A | 1 |
| Di Genova, L | 1 |
| Fattorusso, A | 1 |
| Argentiero, A | 1 |
| Mencaroni, E | 1 |
| Stanford, SC | 1 |
| Geoffroy, PA | 1 |
| Micoulaud Franchi, JA | 1 |
| Lopez, R | 1 |
| Schroder, CM | 1 |
| Amos, LB | 1 |
| Grekowicz, ML | 1 |
| Kuhn, EM | 1 |
| Olstad, JD | 1 |
| Collins, MM | 1 |
| Norins, NA | 1 |
| D'Andrea, LA | 1 |
| Miano, S | 1 |
| Peraita-Adrados, R | 1 |
| O'Neill, B | 1 |
| Gardani, M | 1 |
| Findlay, G | 1 |
| Whyte, T | 1 |
| Cullen, T | 1 |
| Chakraborty, J | 1 |
| Nthenge-Ngumbau, DN | 1 |
| Rajamma, U | 1 |
| Mohanakumar, KP | 1 |
| Alvarez-Icaza González, D | 1 |
| Fresán-Orellana, A | 1 |
| Saracco Alvarez, R | 1 |
| Becerra-Palars, C | 1 |
| Moreno, J | 1 |
| Ontiveros Uribe, MP | 1 |
| Berlanga, C | 1 |
| Heinze, G | 1 |
| Anderson, G | 2 |
| Maes, M | 1 |
| Hardeland, R | 2 |
| Colin-Gonzalez, AL | 1 |
| Aguilera, G | 1 |
| Serratos, IN | 1 |
| Escribano, BM | 1 |
| Santamaria, A | 1 |
| Tunez, I | 1 |
| Tchekalarova, J | 1 |
| Moyanova, S | 1 |
| Fusco, AD | 1 |
| Ngomba, RT | 1 |
| Puustjärvi, A | 1 |
| Raunio, H | 1 |
| Lecklin, A | 1 |
| Kumpulainen, K | 1 |
| Guerlain, J | 1 |
| Paul, A | 1 |
| Rouillon, I | 1 |
| Parodi, M | 1 |
| Garabedian, EN | 1 |
| Loundon, N | 1 |
| McCarter, SJ | 1 |
| Howell, MJ | 1 |
| Maldonado, MD | 2 |
| Pérez-San-Gregorio, MA | 2 |
| Hocking, B | 1 |
| Verster, GC | 1 |
| Feucht, C | 1 |
| Patel, DR | 1 |
| López-Muñoz, F | 1 |
| Molina, JD | 1 |
| Rubio, G | 1 |
| Alamo, C | 1 |
| De Leersnyder, H | 1 |
| Zisapel, N | 1 |
| Laudon, M | 1 |
| Guénolé, F | 1 |
| Baleyte, JM | 1 |
| Vogel, M | 1 |
| Braungardt, T | 1 |
| Meyer, W | 1 |
| Schneider, W | 1 |
| Halmos, T | 1 |
| Suba, I | 1 |
| Haridas, S | 1 |
| Kumar, M | 1 |
| Manda, K | 1 |
| Dagan, Y | 2 |
| Muñoz Barragán, L | 1 |
| Dawson, KA | 1 |
| Bertsche, T | 1 |
| Schulz, M | 1 |
| Malhotra, S | 1 |
| Sawhney, G | 1 |
| Pandhi, P | 1 |
| Huuhka, K | 1 |
| Riutta, A | 1 |
| Haataja, R | 1 |
| Ylitalo, P | 1 |
| Leinonen, E | 1 |
| Touitou, Y | 2 |
| Altun, A | 1 |
| Ugur-Altun, B | 1 |
| Guardiola-Lemaitre, B | 1 |
| Bhattacharjee, Y | 1 |
| Barton, R | 1 |
| Parlaktas, BS | 1 |
| Ozyurt, B | 1 |
| Ozyurt, H | 1 |
| Tunc, AT | 1 |
| Akbas, A | 1 |
| Bob, P | 1 |
| Fedor-Freybergh, P | 1 |
| Ferrier, IN | 1 |
| Johnstone, EC | 1 |
| Crow, TJ | 1 |
| Arendt, J | 2 |
| Wetterberg, L | 2 |
| Aperia, B | 1 |
| Beck-Friis, J | 1 |
| Kjellman, BF | 1 |
| Ljunggren, JG | 1 |
| Nilsonne, A | 1 |
| Petterson, U | 1 |
| Tham, A | 1 |
| Undén, F | 1 |
| Preslock, JP | 1 |
| Karasek, M | 1 |
| Lewy, AJ | 2 |
| Sack, RA | 1 |
| Singer, CL | 1 |
| Mullen, PE | 1 |
| Smith, I | 1 |
| Nir, I | 1 |
| Sandyk, R | 2 |
| Awerbuch, GI | 1 |
| Waldhauser, F | 1 |
| Ehrhart, B | 1 |
| Förster, E | 1 |
| Selmaoui, B | 1 |
| Zhao, ZY | 1 |
| San Martin, M | 1 |
| Bogdan, A | 1 |
| Penev, PD | 1 |
| Zee, PC | 1 |
| Asplund, R | 1 |
| Ishizaki, A | 1 |
| Sugama, M | 1 |
| Takeuchi, N | 1 |
| Pacchierotti, C | 1 |
| Iapichino, S | 1 |
| Bossini, L | 1 |
| Pieraccini, F | 1 |
| Castrogiovanni, P | 1 |
| Smith, JA | 2 |
| Mee, TJ | 2 |
| Barnes, JL | 2 |
| Lerner, AB | 1 |
| Nordlund, JJ | 1 |
| Campbell, KM | 1 |
| Wade, D | 1 |
| Ross, LW | 1 |
| Meyer, GG | 1 |
| Kay, SR | 1 |
| Den Boer, JA | 1 |
| Westenberg, HG | 1 |
| Claustrat, B | 1 |
| Brun, J | 1 |
| Chazot, G | 1 |
| Maurizi, CP | 1 |
| McIntyre, IM | 1 |
| Norman, TR | 1 |
| Burrows, GD | 1 |
| Armstrong, SM | 1 |
| Miles, A | 1 |
| Philbrick, DR | 1 |
| Sack, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Melatonin Dose-effect Relation in Childhood Autism[NCT01780883] | Phase 2 | 34 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy: A Randomized, add-on Placebo-controlled Clinical Trial[NCT03590197] | Phase 4 | 104 participants (Actual) | Interventional | 2018-08-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
47 reviews available for melatonin and Behavior Disorders
| Article | Year |
|---|---|
Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials.
Topics: Humans; Melatonin; Mental Disorders; Metabolic Diseases; Pain, Postoperative; Randomized Controlled | 2022 |
Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antioxidants; Antipsychotic Agents; Blood Glucose; Bo | 2021 |
Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders.
Topics: Aging; Animals; Antioxidants; Biomarkers; Cognition; Humans; Melatonin; Mental Disorders; Mitochondr | 2021 |
The use of melatonin to mitigate the adverse metabolic side effects of antipsychotics.
Topics: Antipsychotic Agents; Humans; Melatonin; Mental Disorders; Metabolic Syndrome | 2021 |
Melatonin: Pharmacology, Functions and Therapeutic Benefits.
Topics: Animals; Antioxidants; Brain; Circadian Rhythm; Humans; Melatonin; Mental Disorders | 2017 |
Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders.
Topics: Animals; Clinical Trials as Topic; Humans; Melatonin; Mental Disorders; Nervous System Diseases; Oxi | 2017 |
Melatonin and periodontal tissues: Molecular and clinical perspectives.
Topics: Animals; Bone and Bones; Dental Implants; Diabetes Mellitus; Humans; Melatonin; Mental Disorders; Mo | 2017 |
Melatonin for Atypical Antipsychotic-Induced Metabolic Adverse Effects: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antipsychotic Agents; Blood Pressure; Humans; Melatonin; Mental Disorders; Metabolic Diseases; Rando | 2018 |
Pediatric sleep disturbances and treatment with melatonin.
Topics: Child; Child Behavior; Humans; Melatonin; Mental Disorders; Neurodevelopmental Disorders; Sleep Wake | 2019 |
Pediatric insomnia: clinical, diagnosis, and treatment.
Topics: Adolescent; Behavior Therapy; Child; Child Behavior Disorders; Chronobiology Disorders; Cognition Di | 2014 |
Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders.
Topics: Humans; Inflammation; Melatonin; Mental Disorders; Neurodegenerative Diseases; Serotonin | 2014 |
Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches.
Topics: Acetamides; Animals; Humans; Indoles; Melatonin; Memory Disorders; Mental Disorders; Pyrans; Recepto | 2016 |
Melatonin, noncoding RNAs, messenger RNA stability and epigenetics--evidence, hints, gaps and perspectives.
Topics: Animals; Circadian Clocks; DNA Methylation; Epigenesis, Genetic; Humans; Melatonin; Mental Disorders | 2014 |
On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress.
Topics: Animals; Antioxidants; Biological Clocks; Circadian Rhythm; Humans; Melatonin; Mental Disorders; Neu | 2015 |
The role of the melatoninergic system in epilepsy and comorbid psychiatric disorders.
Topics: Animals; Comorbidity; Epilepsy; Humans; Melatonin; Mental Disorders | 2015 |
[Drug therapy and the most common drugs for childhood psychiatric disorders].
Topics: Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Child; Humans; Melatonin; Ment | 2016 |
Importance of Rapid Eye Movement Sleep Behavior Disorder to the Primary Care Physician.
Topics: Central Nervous System Depressants; Clonazepam; Diagnosis, Differential; GABA Modulators; Humans; Me | 2016 |
The role of melatonin in the immuno-neuro-psychology of mental disorders.
Topics: Animals; Humans; Melatonin; Mental Disorders | 2009 |
Melatonin and its agonists, circadian rhythms and psychiatry.
Topics: Adult; Aged; Central Nervous System Depressants; Child; Circadian Rhythm; Humans; Melatonin; Mental | 2009 |
Melatonin as a potential therapeutic agent in psychiatric illness.
Topics: Animals; Antioxidants; Humans; Melatonin; Mental Disorders | 2009 |
Herbal medicines in pediatric neuropsychiatry.
Topics: Adolescent; Child; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Herb-Drug Inte | 2011 |
The effects of shift work on physical and mental health.
Topics: Adaptation, Physiological; Adaptation, Psychological; Cardiovascular Diseases; Circadian Rhythm; Cog | 2012 |
[Physiological and pathophysiological role of the circadian clock system].
Topics: Aging; ARNTL Transcription Factors; Blood Coagulation Disorders; Cardiovascular Diseases; Circadian | 2012 |
Circadian rhythm sleep disorders (CRSD).
Topics: Antipsychotic Agents; Chronotherapy; Humans; Melatonin; Mental Disorders; Phototherapy; Sleep Disord | 2002 |
Temporal organization of the brain: Neurocognitive mechanisms and clinical implications.
Topics: Attention; Brain; Chronobiology Phenomena; Cognition; Consciousness; Humans; Melatonin; Mental Disor | 2004 |
[Melatonin. A clinical-pharmacological assessment].
Topics: Aged; Animals; Antioxidants; Dietary Supplements; Drug Interactions; Humans; Melatonin; Mental Disor | 2004 |
The therapeutic potential of melatonin: a review of the science.
Topics: Aging; Animals; Antioxidants; Endocrine System Diseases; Humans; Melatonin; Mental Disorders; Neopla | 2004 |
[Synchronization and desynchronization of the biological clock in man].
Topics: Adult; Child; Chronobiology Disorders; Circadian Rhythm; Homeostasis; Humans; Melatonin; Mental Diso | 2006 |
Melatonin: therapeutic and clinical utilization.
Topics: Cardiovascular Diseases; Circadian Rhythm; Humans; Immune System; Immune System Diseases; Jet Lag Sy | 2007 |
[Melatoninergic receptor agonists and antagonists: therapeutic perspectives].
Topics: Antidepressive Agents; Body Temperature; Circadian Rhythm; Humans; Melatonin; Mental Disorders; Mood | 2007 |
Use of medication in children with psychiatric disorders.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Psychiatry; D | 2007 |
Melatonin, consciousness, and traumatic stress.
Topics: Animals; Cerebral Cortex; Circadian Rhythm; Consciousness; Gene Expression Regulation; Humans; Long- | 2008 |
The pineal gland: basic implications and clinical correlations.
Topics: Adrenal Glands; Animals; Arginine Vasopressin; Brain Neoplasms; Cricetinae; Female; Gonads; Humans; | 1984 |
[Melatonin in humans].
Topics: Adolescent; Adult; Age Factors; Child; Circadian Rhythm; Endocrine System Diseases; Female; Humans; | 1984 |
The endocrinology of the human pineal.
Topics: Acetylserotonin O-Methyltransferase; Animals; Biological Evolution; Child; Circadian Rhythm; Female; | 1981 |
Biorhythms and the biological clock involvement of melatonin and the pineal gland in life and disease.
Topics: Adrenal Glands; Animals; Circadian Rhythm; Female; Humans; Immune System; Melatonin; Mental Disorder | 1995 |
Clinical aspects of the melatonin action: impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions.
Topics: Aging; Circadian Rhythm; Growth; Humans; Immunity; Melatonin; Mental Disorders; Puberty | 1993 |
[Melatonin and biological rhythms: various aspects in human physiopathology].
Topics: Aging; Animals; Circadian Rhythm; Humans; Melatonin; Mental Disorders; Neoplasms; Pineal Gland | 1996 |
Melatonin: a clinical perspective.
Topics: Humans; Melatonin; Mental Disorders; Neuroimmunomodulation; Pineal Gland | 1997 |
Sleep disorders in the elderly.
Topics: Aged; Antidepressive Agents; Benzodiazepines; Comorbidity; Humans; Life Expectancy; Melatonin; Menta | 1999 |
Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry.
Topics: Circadian Rhythm; Humans; Melatonin; Mental Disorders | 2001 |
Circadian Rhythm Sleep Disorders (CRSD) in psychiatry--a review.
Topics: Antipsychotic Agents; Circadian Rhythm; Humans; Melatonin; Mental Disorders; Phototherapy; Selective | 2002 |
Melatonin in humans physiological and clinical studies.
Topics: Adolescent; Adult; Aged; Child; Circadian Rhythm; Endocrine System Diseases; Female; Humans; Hydroco | 1978 |
Melatonin in humans, neuroendocrinological and pharmacological aspects.
Topics: Animals; Circadian Rhythm; Headache; Humans; Light; Melatonin; Mental Disorders; Pineal Gland | 1990 |
Melatonin: a new probe in psychiatric investigation?
Topics: Animals; Bipolar Disorder; Circadian Rhythm; Humans; Light; Melatonin; Mental Disorders; Pineal Glan | 1989 |
Melatonin and psychiatry.
Topics: Animals; Antidepressive Agents; Brain; Chronobiology Phenomena; Depressive Disorder; Humans; Melaton | 1988 |
Light therapy and psychiatry.
Topics: Atenolol; Circadian Rhythm; Depression; Depressive Disorder; Humans; Light; Melatonin; Mental Disord | 1986 |
5 trials available for melatonin and Behavior Disorders
| Article | Year |
|---|---|
Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial.
Topics: Adult; Analysis of Variance; Anthropometry; Antioxidants; Bipolar Disorder; Double-Blind Method; Fem | 2014 |
Prolonged-release melatonin for children with neurodevelopmental disorders.
Topics: Adolescent; Antioxidants; Child; Child, Preschool; Developmental Disabilities; Drug Delivery Systems | 2011 |
The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: A randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anticonvulsants; Antidepressive Ag | 2006 |
[Usefulness of melatonin for developmental sleep and emotional/behavior disorders--studies of melatonin trial on 50 patients with developmental disorders].
Topics: Adolescent; Adult; Affective Symptoms; Child; Child, Preschool; Circadian Rhythm; Developmental Disa | 1999 |
Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin.
Topics: Adult; beta-Endorphin; Blood Platelets; Double-Blind Method; Fear; Female; Fluvoxamine; Humans; Hydr | 1990 |
28 other studies available for melatonin and Behavior Disorders
| Article | Year |
|---|---|
Pharmacological and philosophical considerations for the around-the-clock use of scheduled melatonin to promote sedation and reduce aggression in individuals with serious mental illness: a case report.
Topics: Aggression; Drug Administration Schedule; Duration of Therapy; Humans; Melatonin; Mental Disorders; | 2021 |
Associations between treatment with melatonin and suicidal behavior: a nationwide cohort study.
Topics: Cohort Studies; Humans; Melatonin; Mental Disorders; Risk Factors; Suicidal Ideation; Suicide, Attem | 2022 |
Recent developments in research of melatonin and its potential therapeutic applications.
Topics: Animals; Circadian Rhythm; Humans; Melatonin; Mental Disorders; Neoplasms; Nervous System Diseases; | 2018 |
The use of melatonin in adult psychiatric disorders: Expert recommendations by the French institute of medical research on sleep (SFRMS).
Topics: Adult; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Utilization; France; Guideline Adher | 2019 |
Treatment of pediatric restless legs syndrome.
Topics: Adolescent; Amines; Analgesics; Anticonvulsants; Antioxidants; Benzothiazoles; Child; Child, Prescho | 2014 |
Challenging behaviour and sleep cycle disorder following brain injury: a preliminary response to agomelatine treatment.
Topics: Acetamides; Brain Injuries; Cognition Disorders; Humans; Hypnotics and Sedatives; Male; Melatonin; M | 2014 |
Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease.
Topics: Animals; Convulsants; Dendritic Spines; Disease Models, Animal; Dose-Response Relationship, Drug; Dr | 2014 |
Editorial: The Kynurenine and Melatonergic Pathways in Psychiatric and CNS Disorders.
Topics: Central Nervous System Diseases; Humans; Kynurenine; Melatonin; Mental Disorders; Signal Transductio | 2016 |
Efficiency of Melatonin as Compared to Pentobarbital for Audiometry Brainstem Response in Children With Associated Disorders.
Topics: Adolescent; Audiometry, Evoked Response; Central Nervous System Depressants; Child; Child, Preschool | 2016 |
Maternal cell phone use and behavioral problems in children.
Topics: Cell Phone; Child Behavior; Child, Preschool; Female; Fetal Development; Humans; Melatonin; Mental D | 2009 |
An historical view of the pineal gland and mental disorders.
Topics: History, 17th Century; History, 18th Century; History, 19th Century; History, 20th Century; Humans; | 2011 |
Natural supplements for mental health. Some complementary and alternative therapies may be worth trying.
Topics: Complementary Therapies; Dietary Supplements; Fatty Acids, Omega-3; Folic Acid; Ginkgo biloba; Human | 2011 |
Effects of melatonin should be studied separately in each neurodevelopmental disorder and with specific sleep diagnoses.
Topics: Antioxidants; Developmental Disabilities; Female; Humans; Male; Melatonin; Mental Disorders; Sleep W | 2012 |
Chronic melatonin administration mitigates behavioral dysfunction induced by γ-irradiation.
Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Depressive Disorder; Drug Administration Schedule; G | 2012 |
[Biological potentiality of melatonin].
Topics: Antioxidants; Apoptosis; Brain; Calcification, Physiologic; Cell Division; Humans; Melatonin; Mental | 2002 |
Psychiatric research. Is internal timing key to mental health?
Topics: Animals; Biological Clocks; Chronobiology Disorders; Circadian Rhythm; Clinical Trials as Topic; Hum | 2007 |
Levels of oxidative stress parameters and the protective effects of melatonin in psychosis model rat testis.
Topics: Animals; Antioxidants; Disease Models, Animal; Dizocilpine Maleate; Male; Malondialdehyde; Melatonin | 2008 |
Melatonin/cortisol ratio in psychiatric illness.
Topics: Humans; Hydrocortisone; Male; Melatonin; Mental Disorders; Middle Aged; Schizophrenia | 1982 |
Melatonin and cortisol levels in psychiatric illness.
Topics: Depression; Diagnosis, Differential; Humans; Hydrocortisone; Melatonin; Mental Disorders; Schizophre | 1982 |
Assessment and treatment of chronobiologic disorders using plasma melatonin levels and bright light exposure: the clock-gate model and the phase response curve.
Topics: Circadian Rhythm; Humans; Light; Melatonin; Mental Disorders; Models, Psychological | 1984 |
Multiple sclerosis: the role of the pineal gland in its timing of onset and risk of psychiatric illness.
Topics: Adolescent; Adult; Age of Onset; Aged; Female; Humans; Male; Melanins; Melatonin; Mental Disorders; | 1993 |
Elevated melatonin serum concentrations in psychiatric patients treated with chlorpromazine [proceedings].
Topics: Adolescent; Adult; Chlorpromazine; Humans; Male; Melatonin; Mental Disorders; Middle Aged; Stimulati | 1977 |
The effect of neuroleptic drugs on serum and cerebrospinal fluid melatonin concentrations in psychiatric subjects.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Chlorpromazine; Female; Flupenthixol; Fl | 1979 |
Melatonin: clinical pharmacology.
Topics: Brain; Brain Diseases; Chemical Phenomena; Chemistry; Humans; Liver; Melatonin; Mental Disorders; Sl | 1978 |
Pigmentation and musculoskeletal abnormalities in an aged state hospital population.
Topics: Adult; Aged; Bone Diseases; Dihydroxyphenylalanine; Female; Humans; Male; Melanins; Melatonin; Menta | 1977 |
Paraventricular nucleus-pineal interaction: relevance to tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Brain; Brain Diseases; Dyskinesia, Drug-Induced; Female; Humans; Male | 1992 |
The therapeutic potential for tryptophan and melatonin: possible roles in depression, sleep, Alzheimer's disease and abnormal aging.
Topics: Aging; Animals; Bipolar Disorder; Dementia; Depressive Disorder; Humans; Melatonin; Mental Disorders | 1990 |
Human melatonin response to light at different times of the night.
Topics: Adult; Circadian Rhythm; Female; Humans; Light; Male; Melatonin; Mental Disorders | 1989 |